Improving retinal examination speed and efficiency

Article

Canon Europe, revealed its new CX-1, a world first in retinal imaging technology for the first time at this year's ESCRS Congress.

Canon Europe, revealed its new CX-1, a world first in retinal imaging technology for the first time at this year's ESCRS Congress.

The CX-1 is a compact and portable hybrid retinal camera that combines both Mydriatic and Non-Mydriatic Modes, and switches between the two at the touch of a button.

Early diagnosis of retinal diseases can be critical and Canon indicates that the point of difference for the CX-1 is that it can used for early detection of AMD without the need for special conditions, for example having to eye drops to dilate the pupil.

That's made possible by the camera's ability to take Fundus Autofluorescence (FAF) images in non-mydriatic mode. In the past that has only been possible in mydriatic mode. The advantages, according to Canon, are that the patient diagnostic experience is a much more comfortable one and it can also save time and resource.

Doctors using the equipment can screen for more than one disease, e.g. AMD (Age-related Macular Degeneration), Glaucoma and diabetic retinopathy, with the same unit. This saves time and removes the need for repeat appointments.

Mr. Yoshiyuki Masuko, Senior Director, Medical Systems Division, Canon Europa N.V. said of the CX-1, “As well as a step-forward in medical innovation, the compact and adaptable design of the CX-1 also represents years of in-depth research into the technology needs of ophthalmic examination.

“The advanced imaging technology is used to aid accurate diagnosis whilst considering the patient”s needs with a multi-functional design that makes the diagnosis process as comfortable as possible for them.”

The product will be on sale across the EMEA region at the end of September.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.